- Revenue Cycle Management
- COVID-19
- Reimbursement
- Diabetes Awareness Month
- Risk Management
- Patient Retention
- Staffing
- Medical Economics® 100th Anniversary
- Coding and documentation
- Business of Endocrinology
- Telehealth
- Physicians Financial News
- Cybersecurity
- Cardiovascular Clinical Consult
- Locum Tenens, brought to you by LocumLife®
- Weight Management
- Business of Women's Health
- Practice Efficiency
- Finance and Wealth
- EHRs
- Remote Patient Monitoring
- Sponsored Webinars
- Medical Technology
- Billing and collections
- Acute Pain Management
- Exclusive Content
- Value-based Care
- Business of Pediatrics
- Concierge Medicine 2.0 by Castle Connolly Private Health Partners
- Practice Growth
- Concierge Medicine
- Business of Cardiology
- Implementing the Topcon Ocular Telehealth Platform
- Malpractice
- Influenza
- Sexual Health
- Chronic Conditions
- Technology
- Legal and Policy
- Money
- Opinion
- Vaccines
- Practice Management
- Patient Relations
- Careers
Research recruitment in patient portal check-in; Omicron less likely to lead to long COVID; Pfizer plant could restart production in Q4 - Morning Medical Update
The top news stories in primary care today.
doctor desk © Alena Kryazheva - stock.adobe.com
Research recruitment in patient portal check-in
Researchers at the University of California, Los Angeles recruited 40 times more research patients than usual by adding a study recruitment sheet into patients’ portal preCheck-in forms. Patients who signed up received a patient-reported outcomes survey after their appointment. The success of this method warrants further investigation.
Omicron less likely to lead to long COVID
The Omicron variant is less likely to lead to long COVID, according to a new study published in the International Journal of Infectious Diseases. Similarly, Omicron patients are less likely to report loss of smell or taste. Ongoing vaccinations have experts hopeful that this trend will persist as the virus continues to mutate.
Pfizer plant could restart production in Q4
The Pfizer plant that sustained tornado damage on July 10 may resume production by the beginning of the fourth quarter of 2023. Most of the damage was done to the warehouse and not the production facilities. A temporary warehouse has been set up in the meantime.
